CollPlant Biotechnologies Ltd. Sponsored ADR
CLGN Healthcare Biotechnology
CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.
Follow CLGN
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) EV/Sales
As of 16 October 2026, CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) trades at a EV/Sales of 24.2×. Over the past ten years it has ranged from 2.4× (August 2019) to 398× (January 2023); the current reading is higher than 61% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.0× | (89.57%) |
| FY2024 | 67.1× | 1,448.86% |
| FY2023 | 4.3× | (98.17%) |
| FY2022 | 236× | 2,851.58% |
| FY2021 | 8.0× | (35.58%) |
| FY2020 | 12.4× | (4.25%) |
| FY2019 | 13.0× | 402.48% |
| FY2018 | 2.6× | (95.00%) |
| FY2017 | 51.6× | 0.00% |
| FY2016 | 51.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 23.7× | 12.53% |
| Mar 2026 | 21.1× | 201.15% |
| Dec 2025 | 7.0× | (43.87%) |
| Sep 2025 | 12.5× | 203.90% |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AIM AIM ImmunoTech Inc. compare | −69.6× |
| SYBX Synlogic, Inc. compare | −0.2× |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| CALC CalciMedica Inc. compare | n/m |
| XCUR Exicure, Inc. compare | 0.2× |
| NIKI Niki BioSolutions, Inc. compare | 1.3× |
| SKYE Skye Bioscience, Inc. compare | 12.9× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR | 24.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)